Overview


According to FutureWise analysis the market for HERG screening in 2023 is US$ 1.01 billion, and is expected to reach US$ 2.64 billion by 2031 at a CAGR of 12.72%.

The HERG or the human Ether-a-go-go-Related Gene is a gene that codes for the protein known as Kvll .1, the alpha Subunit of a potassium-ion channel. Its channels regulate the This helps to regulate the heartbeat by supplying a repolarizing current to the cardiac action potential. The HERG assessments are Now, this was one of the prior requirements of the regulatory agencies before submission of the Investigational new drug. Some assays for the HERG screening look like a manual or automatic patch clamp assay. HERG radio ligand binding test, fluorescence polarization analysis, and microelectrode array. Automatic patch clamp Assay the HERG current in various concentrations. It is recorded before and after it has been exposed to the air. test compounds. The technique known as dose formulation analysis determines the IC50 values. Likewise, The other assays can also be performed according to their respective norms. There are many benefits to HERG screening. It has the presence channel, which serves as the target for medications used to treat class Ill arrhythmias such as amiodarone.

Due to its large action potential, re-entrant arrhythmias are less likely. Additionally, it can be used to treat the HERG screening can be used to identify cancer, recurring epileptic seizures, schizophrenia, and other illnesses. HERG screening is mostly used to reveal drugs. In the future, hERG screening will be supported by the increasing number of item dispatches. According to the Center for Drug Evaluation and Research's (CDER) annual report, 25 new medications were given endorsement for promotion. To help the medication disclosure measure, which helps the hERG screening industry sector grow, the number of novel medication endorsements is increasing. The HERG screening market is being driven by the increasing number of novel drugs approvals and rising prevalence of heart disease. The high cost of HERG screening products will likely limit the market's growth over the forecast period. Untapped markets will offer a lucrative opportunity to grow this market in the future.

The Market will be driven by the Increasing prevalence of heart disease and rising number of heart patients. The market is growing. The market is also being driven by an increase in R&D for new product launches. The market is growing. The market will also benefit from an increase in approvals for new drug entities. Market growth. Increased demand for drug formulations and the development of drugs to treat diseases. Market growth can also be aided by disorders. Moreover, the market faces increasing challenges. The application is a biotechnological product or a pharmaceutical product that helps to create opportunities for the HERG screening market is growing. The high price of HERG screening products will likely hinder the growth of HERG screening. market.

FutureWise Market Research has instantiated a report that provides an intricate analysis of HERG Screening Market trends that shall affect the overall market growth. Furthermore, it includes detailed information on the graph of profitability, SWOT analysis, market share and regional proliferation of this business. Moreover, the report offers insights on the current stature of prominent market players in the competitive landscape analysis of this market.

According to the research study conducted by FutureWise research analysts, the HERG Screening Market is anticipated to attain substantial growth by the end of the forecast period. The report explains that this business is predicted to register a noteworthy growth rate over the forecast period. This report provides crucial information pertaining to the total valuation that is presently held by this industry and it also lists the segmentation of the market along with the growth opportunities present across this business vertical.

  • Abcam PLC
  • ABR-Affinity Bioreagents Inc
  • AstraZeneca Plc
  • Aureus Sciences
  • Aurora Biomed Inc
  • AVIVA Biosciences
  • B'SyS GmbH
  • Caliper
  • A PerkinElmer Company
  • Cambridge Bioscience Ltd
  • Cellular Dynamics
  • Eurofins-Cerep SA
  • ChanTest Corporation
  • Charles River Laboratories Inc
  • ChemAxon
  • Molecular Devices LLC

(Note: The list of the major players will be updated with the latest market scenario and trends)

By Product Type

  • Gene KCNH2
  • Mutant KCNH2
  • Others

By Ion Channel

  • Voltage Gated
  • Ligand Gated
  • Others

By Application

  • Antiarrhythmic
  • Antipsychotic
  • Antibiotic
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the HERG Screening Market By Product Type, By Ion Channel, By Application and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   HERG Screening Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of HERG Screening Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   HERG Screening Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   HERG Screening Market, By Product Type Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Gene KCNH2
        2. Mutant KCNH2
        3. Others

  • 8.   HERG Screening Market, By Ion Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Voltage Gated
        2. Ligand Gated
        3. Others

  • 9.   HERG Screening Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Antiarrhythmic
        2. Antipsychotic
        3. Antibiotic
        4. Others

  • 10.   North America HERG Screening Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America HERG Screening Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe HERG Screening Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific HERG Screening Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Abcam PLC
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. ABR-Affinity Bioreagents Inc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. AstraZeneca Plc
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Aureus Sciences
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Aurora Biomed Inc
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. AVIVA Biosciences
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. B'SyS GmbH
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Caliper
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. A PerkinElmer Company
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Cambridge Bioscience Ltd
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Cellular Dynamics
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Eurofins-Cerep SA
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. ChanTest Corporation
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Charles River Laboratories Inc
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. ChemAxon
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview
        16. Molecular Devices LLC
          16. 1. Company Overview
          16. 2. Product Portfolio
          16. 3. SWOT Analysis
          16. 4. Financial Overview
          16. 5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients